

## Ethnicity association of *Helicobacter pylori* virulence genotype and metronidazole susceptibility

Hanafiah Alfizah, Awang Hamat Rukman, Ahmad Norazah, Razlan Hamizah, Mohamed Ramelah

Hanafiah Alfizah, Department of Medical Microbiology and Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000 Cheras, Kuala Lumpur, Malaysia  
Awang Hamat Rukman, Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia  
Ahmad Norazah, Bacteriology Unit, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia  
Razlan Hamizah, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000 Cheras, Kuala Lumpur, Malaysia  
Mohamed Ramelah, Centre for Innovative Collaboration, Universiti Kebangsaan Malaysia, 43600 Bangi, Selangor, Malaysia  
Author contributions: All authors contributed equally in this study.

Supported by Grant from the Ministry of Science, Technology and Innovation, Malaysia, No. 06-02-0055-PR0073/05  
Correspondence to: Hanafiah Alfizah, PhD, Department of Medical Microbiology and Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. [alfizah@ppukm.ukm.edu.my](mailto:alfizah@ppukm.ukm.edu.my)  
Telephone: +60-3-91455442 Fax: +60-3-91456671  
Received: October 17, 2012 Revised: December 29, 2012  
Accepted: January 11, 2013  
Published online: February 28, 2013

### Abstract

**AIM:** To characterise the *cag* pathogenicity island in *Helicobacter pylori* (*H. pylori*) isolates by analysing the strains' *vacA* alleles and metronidazole susceptibilities in light of patient ethnicity and clinical outcome.

**METHODS:** Ninety-five *H. pylori* clinical isolates obtained from patients with dyspepsia living in Malaysia were analysed in this study. Six genes in the *cagPAI* region (*cagE*, *cagM*, *cagT*, *cag13*, *cag10* and *cag67*) and *vacA* alleles of the *H. pylori* isolates were identified by polymerase chain reaction. The isolates' metronidazole susceptibility was also determined using the *E*-test

method, and the resistant gene was characterised by sequencing.

**RESULTS:** More than 90% of the tested isolates had at least one gene in the *cagPAI* region, and *cag67* was predominantly detected in the strains isolated from the Chinese patients, compared with the Malay and Indian patients ( $P < 0.0001$ ). The majority of the isolates (88%) exhibited partial deletion (rearrangement) in the *cagPAI* region, with nineteen different patterns observed. Strains with intact or deleted *cagPAI* regions were detected in 3.2% and 8.4% of isolates, respectively. The prevalence of *vacA* s1m1 was significantly higher in the Malay and Indian isolates, whereas the isolates from the Chinese patients were predominantly genotyped as *vacA* s1m2 ( $P = 0.018$ ). Additionally, the isolates from the Chinese patients were more sensitive to metronidazole than the isolates from the Malay and Indian patients ( $P = 0.047$ ). Although we attempted to relate the *cagPAI* genotypes, *vacA* alleles and metronidazole susceptibilities to disease outcome, no association was observed. The *vacA* alleles were distributed evenly among the strains with intact, partially deleted or deleted *cagPAI* regions. Interestingly, the strains exhibiting an intact *cagPAI* region were sensitive to metronidazole, whereas the strains with a deleted *cagPAI* were more resistant.

**CONCLUSION:** Successful colonisation by different *H. pylori* genotypes is dependent on the host's genetic makeup and may play an important role in the clinical outcome.

© 2013 Baishideng. All rights reserved.

**Key words:** *Helicobacter pylori*; *cag* pathogenicity island; *vacA* alleles; Metronidazole susceptibility

Alfizah H, Rukman AH, Norazah A, Hamizah R, Ramelah M. Ethnicity association of *Helicobacter pylori* virulence genotype and metronidazole susceptibility. *World J Gastroenterol*

## INTRODUCTION

*Helicobacter pylori* (*H. pylori*) demonstrates great genetic diversity, as evidenced by the apparently unlimited number of unique strains differing in genome size, gene order, gene content and allelic profile<sup>[1]</sup>. The high levels of genetic diversity in clinical isolates and the presence of certain virulence genotypes may confer a selective advantage to certain strains in different hosts. Therefore, the virulence genotype of *H. pylori* is a potentially useful predictor of the clinical outcome of gastric mucosal colonisation.

*H. pylori* possess a number of virulence determinants that modulate the organism's interaction with a host<sup>[2,3]</sup>. These virulence factors include the secreted, vacuolating cytotoxin VacA and the gene products of the pathogenicity island (*cagPAI*). The presence of these genetic loci correlates with the more severe *H. pylori*-associated pathologies, peptic ulcers and gastric cancer. Screening for the *cagPAI* genes is frequently performed due to the genes' involvement in virulence characteristics. An infection with *cagPAI*-positive *H. pylori* strains significantly increases the risk of developing severe gastric mucosal inflammation, duodenal ulceration and gastric cancer<sup>[4-6]</sup>. It has been observed that only one-half to two-thirds of isolates from Western patients express the *cagPAI* region, whereas almost all of the East Asian strains express this region. As there is limited information on the structure of the *cagPAI* in Malaysian patients, the role of *cagPAI* rearrangement in *H. pylori* isolates from various ethnic populations within this country should be investigated.

The *vacA* gene is another *H. pylori* virulence factor that exhibits great polymorphism and diverse allelic combination. The variable structure, resulting in different allelic arrangements in the gene, is related to differences in cytotoxin production and to the distinct clinical outcomes of *H. pylori* infection<sup>[7-9]</sup>. For example, a recent study performed at our institute has demonstrated a correlation between the presence of genetic polymorphisms in the *vacA* gene and the severity of gastritis<sup>[10]</sup>.

*H. pylori* infection can be effectively cured by antibiotics. More specifically, metronidazole is commonly used in conjunction with either amoxicillin or clarithromycin and a proton-pump inhibitor to eradicate *H. pylori* infection<sup>[11,12]</sup>. Metronidazole is also used in the treatment of other diseases, such as gynaecological infections, and has contributed to the increased antibiotic resistance of *H. pylori*<sup>[13]</sup>. In Malaysia, the prevalence of metronidazole-resistant strains is 37%, which may be one of the factors contributing to the failed eradication of *H. pylori* infection in the country<sup>[14]</sup>.

The population of Malaysia consists of three major

ethnic groups (Malay, Chinese and Indian) that are historically associated with differences in *H. pylori* infection<sup>[15-17]</sup>. *H. pylori*-associated gastroduodenal diseases typically do not reflect the prevalence of *H. pylori* infection<sup>[15]</sup>. Furthermore, geographical and population differences in *H. pylori* virulence factors and disease severity underscore the importance of investigating the relationship between the genotypes of the causative strains and the clinical outcome. Therefore, to further understand the dynamics of the genetic traits of the *H. pylori cagPAI* regions, *vacA* alleles and metronidazole susceptibilities in Malaysia's multi-ethnic population, we investigated the possible association between these *H. pylori* virulence factors and infection in patients of different ethnicities and clinical outcomes.

## MATERIALS AND METHODS

### Patients

Patients with dyspepsia who had undergone an upper gastrointestinal scope (OGDS) at Universiti Kebangsaan Malaysia Medical Centre (Kuala Lumpur, Malaysia) between May 2004 and December 2007 were recruited. Any patients who had received antibiotics 4 wk prior to OGDS were excluded. Written informed consent was obtained from each patient, and the protocol was approved by the Research Ethics Committee (protocol number FF-075-2003) of the University.

### *H. pylori* culture

Biopsies were subcultured for *H. pylori* on Columbia agar base (Oxoid, Basingstoke, England) containing Dent's supplement (Oxoid, Basingstoke, England) and 7% defibrinated sheep blood. The plates were incubated at 37 °C for 5 d under microaerophilic conditions.

### DNA extraction

*H. pylori* genomic DNA was prepared using a High Pure polymerase chain reaction (PCR) Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions.

### Detection of metronidazole susceptibility and resistance genotype

Metronidazole susceptibility was determined using the E-test method (AB Biodisk, Solna, Sweden). First, an *H. pylori* culture suspension with a McFarland turbidity of 3.0 was used to inoculate Columbia agar supplemented with 10% defibrinated sheep blood. The plates were then incubated at 35 ± 2 °C for 3-5 d under microaerophilic conditions. The isolates were classified as resistant to metronidazole when the MIC value was > 8 µg/mL<sup>[18]</sup>. The *rdxA* genes were amplified by PCR using specific primers, as previously described<sup>[19]</sup>, and then subjected to sequencing.

### Detection of *cagPAI* genes

Two loci were selected in the *cag* I region (*cagE* and

*cagM*), and four loci were chosen from the *cagII* region (*cagT*, *cag13*, *cag10* and *cag67*). Additionally, the insertion sequence IS605 was selected. The presence of these selected genes was determined by PCR using specific primers, as previously described<sup>[20]</sup>. PCR was conducted in 25  $\mu$ L volumes containing 1  $\times$  PCR buffer, 0.2 mmol/L dNTP mix, 10 pmol of each primer, 1 U Taq polymerase (BioTherm, GeneCraft, Germany) and 1  $\mu$ L of the DNA sample. The PCR amplification conditions consisted of 35 cycles at 94  $^{\circ}$ C for 1 min, 50–55  $^{\circ}$ C for 30 s, 72  $^{\circ}$ C for 1 min, and one cycle for the final extension at 72  $^{\circ}$ C for 10 min. The amplified product was electrophoresed on a 1% agarose gel.

### Detection of *vacA* alleles

The *vacA* genotyping was performed by multiplex PCR using specific primers, as previously described<sup>[10,21]</sup>. PCR was conducted in 25- $\mu$ L volumes containing 1  $\times$  PCR buffer, 0.2 mmol/L dNTP mix, 6 pmol of each primer, 0.75 U Taq polymerase (BioTherm, GeneCraft, Germany) and 1  $\mu$ L of the DNA sample. The PCR amplification conditions consisted of an initial denaturation step at 94  $^{\circ}$ C for 4 min, followed by 30 cycles of denaturation at 94  $^{\circ}$ C for 30 s, primer annealing at 55  $^{\circ}$ C for 30 s, extension at 72  $^{\circ}$ C for 30 s, and one cycle for the final extension at 72  $^{\circ}$ C for 7 min. The amplified products were electrophoresed on a 1.5% agarose gel.

### Statistical analysis

A statistical analysis was performed using the  $\chi^2$  test. A value of  $P < 0.05$  was considered statistically significant.

## RESULTS

### *H. pylori* clinical isolates

A total of 95 clinical *H. pylori* isolates were obtained from 40 male and 55 female patients with a mean age of  $55.47 \pm 16.87$  years (age range of 17–89 years) and from three different ethnic groups (12 Malays, 59 Chinese and 24 Indians). The endoscopic findings were as follows: nonulcer dyspepsia ( $n = 76$ ), gastric ulcer ( $n = 9$ ), duodenal ulcer ( $n = 6$ ) and both gastric and duodenal ulcers ( $n = 2$ ). The OGDS findings were not available for two of the patients. Nonulcer dyspepsia was further classified as endoscopically normal stomach ( $n = 12$ ), antrum-predominant gastritis ( $n = 43$ ), corpus-predominant gastritis ( $n = 2$ ) and pangastritis ( $n = 19$ ). No significant association was found between patient ethnicity (Chinese versus non-Chinese) and the endoscopic findings (non-ulcer dyspepsia versus peptic ulcer).

### *cagPAI* genotype

Of the 95 *H. pylori* isolates, 87 (91.6%) were *cagPAI*-positive, and the remaining 8 (8.4%) lacked all selected *cagPAI* genes. For the *cagPAI*-positive strains, intact *cagPAI* genes were detected only in 3 isolates, whereas other isolates exhibited partially deleted (rearranged) *cagPAI*

**Table 1** Distribution of *Helicobacter pylori cagPAI* genes isolated from patients of different ethnicities  $n$  (%)

<i>cagPAI</i> genes	Ethnic groups			<i>P</i> value
	Malay	Chinese	Indian	
<i>cagI</i> region				
<i>cagE</i>	7 (58.3)	41 (69.5)	14 (58.3)	0.541
<i>cagM</i>	9 (75.0)	45 (76.3)	19 (79.2)	0.948
<i>cagII</i> region				
<i>cagT</i>	11 (91.7)	49 (83.1)	18 (75.0)	
<i>cag13</i>	0	4 (6.8)	0	
<i>cag10</i>	6 (50.0)	29 (49.2)	16 (66.7)	0.336
<i>cag67</i>	6 (50.0)	47 (79.7)	5 (20.8)	< 0.0001

genes. Additionally, the IS605 gene was detected in 4 (4.2%) isolates. Further analyses indicated that the positivity of the *H. pylori* isolates was 61.1% (58/95), 53.7% (51/95), 4.2% (4/95), 82.1% (78/95), 76.8% (73/95) and 65.3% (62/95) for *cag67*, *cag10*, *cag13*, *cagT*, *cagM* and *cagE*, respectively.

As shown in Table 1, the presence of *cagE* and *cagM* in the *cagI* region was distributed evenly among the isolates from patients of different ethnicities, with no significant differences between the ethnicities. The *cagT* gene was frequently detected in isolates from the Malay patients, whereas *cag13* was only detected in the isolates from the Chinese patients. The presence of *cag67* was significantly higher in the isolates from the Chinese patients than in the isolates from the Malay patients and was lowest in the isolates from the Indian patients. The *cagPAI* genes were detected in greater than 50% of the isolates from the nonulcer and ulcer patients, except for *cag13*, which was only detected in the patients with a normal stomach or gastritis. Thus, different *cagPAI* genes were present in the majority of the isolates examined, irrespective of disease state.

Of the 95 clinical isolates, only 3 (3.2%) contained an intact *cagPAI*, whereas 84 (88.4%) exhibited partial deletions within the *cagPAI* region, and 8 (8.4%) lacked the entire selected gene in the *cagPAI*. As shown in Table 2, thirteen isolates appeared to have a diverged *cagPAI*, in which the two selected genes for the *cagI* region had been deleted, although the genes in the *cagII* region were conserved, with at least one gene present. In contrast, ten strains had only one gene in either the *cagI* or the *cagII* region. The single gene detected was *cagM*, *cagT* and *cag67* in 3, 6 and 1 isolate, respectively. The most commonly partially deleted *cagPAI* genotypes were detected in 26 (27.4%), 16 (16.8%) and 13 (13.7%) isolates, with *cagPAI* regions of types C, I and N, respectively. These isolates exhibited at least four genes in the *cagPAI* region, and the genes in the *cagI* region were conserved in these isolates. Additionally, the IS605 gene was detected in the isolates from the Chinese ( $n = 2$ ) and Indian ( $n = 2$ ) patients. Three of these isolates contained all of the selected genes for *cagPAI*, except *cag13*, and one isolate lacked the *cag13* and *cag10* genes.

As shown in Table 3, three isolates with an intact *cag*-

**Table 2** *cagPAI* genotypes of *Helicobacter pylori* clinical isolates *n* (%)

<i>cagPAI</i> type	<i>cag</i> II region				<i>cag</i> I region		Total
	<i>cag67</i>	<i>cag10</i>	<i>cag13</i>	<i>cagT</i>	<i>cagM</i>	<i>cagE</i>	
A	+	+	+	+	+	+	3 (3.2)
B	+	-	+	-	-	-	1 (1.1)
C	+	+	-	+	+	+	26 (27.4)
D	+	+	-	+	+	-	2 (2.1)
E	+	+	-	-	+	+	1 (1.1)
F	+	+	-	-	+	-	1 (1.1)
G	+	+	-	-	-	-	1 (1.1)
H	+	-	-	-	-	-	1 (1.1)
I	+	-	-	+	+	+	16 (16.8)
J	+	-	-	+	+	-	2 (2.1)
K	+	-	-	+	-	+	1 (1.1)
L	+	-	-	-	+	+	1 (1.1)
M	+	-	-	+	-	-	2 (2.1)
N	-	+	-	+	+	+	13 (13.7)
O	-	+	-	+	+	-	2 (2.1)
P	-	+	-	+	-	-	2 (2.1)
Q	-	-	-	+	+	+	1 (1.1)
R	-	-	-	+	+	-	2 (2.1)
S	-	-	-	+	-	-	6 (6.3)
T	-	-	-	-	+	-	3 (3.2)
U	-	-	-	-	-	-	8 (8.4)

PAI were obtained from the Chinese patients. Nineteen of the 59 (32.2%) isolates from the Chinese patients possessed partially deleted *cagPAI* regions of type C, compared with 25% and 16.7% of the isolates from the Malay and Indian patients, respectively. Interestingly, the isolates from the Indian patients showed a high proportion of partially deleted *cagPAI* regions of type N (37.5%) and deleted *cagPAI* regions (16.7%). An analysis of the disease state, with reference to strain genotype, revealed a relationship between the *cagPAI* genotype and disease severity. The isolates from those patients with peptic ulcer disease (PUD) primarily exhibited *cagPAI* regions of type C, which contained more genes in the rearranged *cagPAI* genotypes. In contrast, a larger number of isolates from the patients with pangastritis or antrum-predominant gastritis possessed *cagPAI* regions of type I or N, respectively, compared with the isolates from the patients with peptic ulcers.

### *vacA* genotype

The *vacA* s1m1, s1m2 and s2m2 genotypes were identified in 51.6% (49/95), 42.1% (40/95) and 4.2% (4/94) of the isolates, respectively. Additionally, two (2.1%) isolates possessed the *vacA* s1m1m2 genotype. The *vacA* s1m1 genotype was further classified as *vacA* s1am1 (63.3%, 31/49), s1cm1 (22.4%, 11/49) or s1as1cm1 (14.3%, 7/49), and the *vacA* s1m2 genotype was further classified as *vacA* s1am2 (65%, 26/40), s1cm2 (22.5%, 9/40) or s1as1cm2 (12.5%, 5/40). An analysis of the distribution of the *vacA* alleles with respect to patient ethnicity and disease state is shown in Table 4. We found a significant distribution of different *vacA* alleles according to patient ethnicity. The *vacA* s1m1 genotype

was significantly more prevalent in the isolates from the Malay and Indian patients, whereas the *vacA* s1m2 genotype was predominantly detected in the isolates from the Chinese patients ( $P = 0.018$ ). The *vacA* s2m2 genotype was only isolated from the Malay and Indian patients, and a mixed genotype of the m region was identified in the isolates from the Chinese patients. Further analyses of the *vacA* subgenotypes with respect to patient ethnicity revealed that the highest proportion of isolates harbouring the *vacA* s1am1 subgenotype were from Indian patients (93.8%, 15/16). The prevalence of the *vacA* s1cm1 genotype was similar in proportion in the isolates from the Malay (37.5%, 3/8) and Chinese (32%, 8/25) patients, although this subgenotype was not detected in the isolates from the Indian patients. In contrast, the *vacA* s1am2 subgenotype was detected in all of the ethnic groups, whereas the *vacA* s1cm2 subgenotype was only identified in the isolates from the Chinese patients. No significant difference was observed in the distribution of the *vacA* s1m1 and s1m2 strains with respect to the disease state ( $P = 0.686$ ).

### Metronidazole susceptibility

In this study, metronidazole resistance was observed in 45.3% (43/95) of the isolates. The resistant strains exhibited MIC values ranging from 8 to > 256 mg/L, with an MIC value > 256 mg/L for the majority of the strains (62.8%, 27/43). As shown in Table 4, a strong association was observed between metronidazole susceptibility and patient ethnicity. The Chinese patients were more prone to infection with metronidazole-sensitive *H. pylori* strains, whereas the Malay and Indian patients were more likely to be infected with the antibiotic-resistant strains. The strains isolated from the patients with PUD were more sensitive to metronidazole than the strains from the patients with pangastritis, although this difference was not statistically significant. DNA sequence analyses of the *ndxA* gene revealed the presence of missense, frameshift and nonsense mutations in 30, 3 and 4 isolates, respectively. All of the tested metronidazole-sensitive strains harboured only missense mutations, whereas all three types of mutations were identified in the antibiotic-resistant strains.

### Distribution of *H. pylori cagPAI* genotypes, *vacA* alleles and metronidazole susceptibilities

As shown in Table 5, the isolates with intact *cagPAI* regions carrying the *vacA* s1m2 allele were sensitive to metronidazole. Of the isolates with a rearranged *cagPAI* region, the type C strains predominantly harboured the *vacA* s1m2 allele, whereas a high proportion of the types I and N *cagPAI* strains harboured the *vacA* s1m1 allele. However, these strains were found to be more sensitive to metronidazole. In contrast, the isolates exhibiting a deleted *cagPAI* region predominantly carried the *vacA* s1m2 allele and were more resistant to metronidazole.

**Table 3** Distribution of strains with intact, partially deleted (rearranged) or deleted *cagPAI* regions among patients of different ethnicities and disease states *n* (%)

<i>cagPAI</i> status	Ethnic group			Disease state			
	Malay ( <i>n</i> = 12)	Chinese ( <i>n</i> = 59)	Indian ( <i>n</i> = 24)	Normal ( <i>n</i> = 12)	Gastritis (antral) ( <i>n</i> = 43)	Pangastritis ( <i>n</i> = 19)	PUD ( <i>n</i> = 17)
Intact							
Type A	0	3 (5.1)	0	1 (8.3)	2 (4.7)	0	0
Partially deleted							
Type C	3 (25.0)	19 (32.2)	4 (16.7)	3 (25.0)	9 (20.9)	7 (36.8)	7 (41.2)
Type I	2 (16.7)	14 (23.7)	0	2 (16.7)	5 (11.6)	5 (26.3)	3 (17.6)
Type N	2 (16.7)	2 (3.4)	9 (37.5)	1 (8.3)	7 (16.3)	2 (10.5)	2 (11.8)
Deleted							
Type U	1 (8.3)	3 (5.1)	4 (16.7)	1 (8.3)	3 (7.0)	1 (5.3)	2 (11.8)

PUD: Peptic-ulcer disease.

**Table 4** Distribution of *vacA* alleles and metronidazole susceptibilities among *Helicobacter pylori* clinical isolates from patients of different ethnicities and disease states *n* (%)

<i>cagPAI</i> status	Ethnic group			Disease state			
	Malay ( <i>n</i> = 12)	Chinese ( <i>n</i> = 59)	Indian ( <i>n</i> = 24)	Normal ( <i>n</i> = 12)	Gastritis (antral) ( <i>n</i> = 43)	Pangastritis ( <i>n</i> = 19)	PUD ( <i>n</i> = 17)
Intact							
Type A	0	3 (5.1)	0	1 (8.3)	2 (4.7)	0	0
Partially deleted							
Type C	3 (25.0)	19 (32.2)	4 (16.7)	3 (25.0)	9 (20.9)	7 (36.8)	7 (41.2)
Type I	2 (16.7)	14 (23.7)	0	2 (16.7)	5 (11.6)	5 (26.3)	3 (17.6)
Type N	2 (16.7)	2 (3.4)	9 (37.5)	1 (8.3)	7 (16.3)	2 (10.5)	2 (11.8)
Deleted							
Type U	1 (8.3)	3 (5.1)	4 (16.7)	1 (8.3)	3 (7.0)	1 (5.3)	2 (11.8)

PUD: Peptic-ulcer disease.

## DISCUSSION

The *cagPAI* and *vacA* genotypes are widely used to characterise the virulence of *H. pylori* and the relationship of such virulence to disease severity, although direct associations with peptic ulcers and gastric cancer have not been established<sup>[22,23]</sup>. Rather, the development of severe histological changes in the gastric mucosa may depend on the synergistic effect of bacterial and host factors<sup>[24]</sup>.

The genotypic characteristics of the *H. pylori* *cagPAI* genes show great variability worldwide. The rearrangement of the *cagPAI* varies between different populations and geographical regions, with variations of 50%–65% in areas of the Indian subcontinent<sup>[25,26]</sup>, 32% in France<sup>[27]</sup>, 9% in Sweden<sup>[28]</sup> and the United States<sup>[29]</sup> and 1% in Japan<sup>[30]</sup>. In the present study, more than 90% of the clinical isolates were positive for at least one of the selected *cagPAI* genes. The *cagPAI* genes tested in this study did not include the *cagA* gene, as we previously demonstrated<sup>[31]</sup> that the majority of the *H. pylori* strains circulating in our study population were *cagA*-positive. In the six genetic loci studied, the most frequently deleted gene was *cagI3*, and the least frequently deleted gene was *cagT*. The IS605 insertion sequence was present in less than 5% of the *H. pylori* isolates examined, and the majority of the isolates harboured a rearranged *cagPAI* gene. Analyses of

the individual *cagPAI* genes showed that *cag67* was more conserved in the isolates from the Chinese patients, whereas the rearrangement of *cagE* occurred at a higher frequency in the isolates from the Malay and Indian patients, although this difference was not significant.

We also observed that the majority of the *H. pylori* clinical isolates expressed partially deleted *cagPAI* regions and that only few isolates exhibited either intact or deleted *cagPAI* regions. Previous studies have reported the occurrence of different proportions of intact *cagPAI* in their isolates. Ali *et al.*<sup>[32]</sup> found that 37.4% of isolates exhibited intact *cagPAI* regions, whereas other researchers<sup>[30,33]</sup> reported that more than 96% of isolates contained intact *cagPAI*. In the present study, the isolates expressing intermediate genotypes (deletions within the *cagPAI* region) were more commonly encountered than those isolates with intact or deleted *cagPAI* regions. Moreover, a large proportion of the isolates exhibiting *cagPAI* rearrangement lacked an IS605 sequence, suggesting that this insertion sequence did not play a role in *cagPAI* disruption in the clinical isolates.

Additionally, we found that no single gene in the *cagPAI* region can be used as a genetic marker for an intact *cagPAI* because a large proportion of the clinical isolates exhibited gene rearrangement in the *cagPAI* region. Due

**Table 5** Distribution of *Helicobacter pylori* *cagPAI* genotypes, *vacA* alleles and metronidazole susceptibilities *n* (%)

<i>cagPAI</i> status	<i>vacA</i>		Metronidazole susceptibility		<i>vacA</i> /metronidazole susceptibility			
	s1m1	s1m2	Sensitive	Resistant	s1m1/sensitive	s1m1/resistant	s1m2/sensitive	s1m2/resistant
Intact ( <i>n</i> = 2) <sup>1</sup>	0	2 (100)	2 (100)	0	0	0	2 (100)	0
Partially deleted								
Type C ( <i>n</i> = 26)	10 (38.5)	16 (61.5)	14 (53.8)	12 (46.2)	5 (19.2)	5 (19.2)	9 (34.6)	7 (26.9)
Type I ( <i>n</i> = 16)	12 (75.0)	4 (25.0)	10 (62.5)	6 (37.5)	7 (43.8)	5 (31.2)	3 (18.8)	1 (6.2)
Type N ( <i>n</i> = 13)	11 (84.6)	2 (15.4)	8 (61.5)	5 (38.5)	7 (53.8)	4 (50.0)	1 (12.5)	1 (12.5)
Deleted ( <i>n</i> = 6) <sup>2</sup>	1 (16.7)	5 (83.3)	3 (37.5)	5 (62.5)	0	1 (16.7)	2 (33.3)	3 (50.0)

<sup>1</sup>One strain with the *vacA* s1m1m2 genotype was not included; <sup>2</sup>Two strains with the *vacA* s2m2 genotype were not included.

to the region's large size (approximately 40 kbp), the absence of these genes in certain clinical isolates did not necessarily indicate the complete absence of the *cagPAI*, as indicated in 9 isolates positive for a single gene. Regarding *cagPAI* rearrangement, 19 different genotypes (types B to T) have been identified. The three most common *cagPAI* genotypes identified in the clinical strains revealed that the genes at the left end of the *cagPAI* region were more unstable and prone to rearrangement than the genes in the middle and at the right end of the *cagPAI* region. This finding was supported by analyses of the individual genes, which demonstrated more gene rearrangement at the left end of the *cagPAI* region (*cag13*, *cag10* and *cag67*). Therefore, the genes in the middle and at the right end of the *cagPAI* region may play an important role in the pathogenesis of *H. pylori* infection in the study population.

In the current study, specific *cagPAI* genotypes were isolated from patients of different ethnicities. All of the isolates with intact *cagPAI* regions and less *cagPAI* rearrangement were from the Chinese patients, whereas the Indian patients were infected with strains exhibiting more rearranged or deleted *cagPAI* regions, and the Malay patients tended to be infected with various *cagPAI* genotypes. Thus, the presence of different *cagPAI* genotypes in different ethnicities may be related to the genetic characteristics of both the colonising *H. pylori* strain and the host. Although the relationship between the *cagPAI* genotype and disease state was unclear, we observed that certain types of infecting strains exhibited different *cagPAI* rearrangements in nonulcer and ulcer patients.

A significant difference was observed in the prevalence of *vacA* genotypes among patients of distinct ethnicities. As the Chinese patients were more likely to be infected with the *vacA* s1m2 strains, these strains may be regarded as more pathogenic, consistent with previous reports showing a higher frequency of peptic ulcers and gastric cancer in the Chinese patients in a similar study population<sup>[15,34]</sup>. In our study population, the smaller proportion of patients with PUD than NUD may have contributed to the lack of a significant association between the endoscopic findings and patient ethnicity, as analysis was conducted on the samples with positive cultures. Additionally, we demonstrated that the *vacA* s1m2 genotype was significantly associated with enhanced gas-

tric inflammation<sup>[10]</sup>. In contrast, the *vacA* s2m2 strains were isolated only from the Malay and Indian patients, suggesting that these strains are less virulent. Consistent with this finding, Chinese ethnicity has been associated with infection by strains lacking the *vacA* s2m2 allele<sup>[35,36]</sup>. As Miernyk *et al.*<sup>[37]</sup> recently reported a high proportion of *vacA* s2m2 strains isolated from Alaskan natives, it would be interesting to examine whether the disease outcome in Alaskan natives is similar to the outcome in the Malay and Indian patients in our study population. The current study also revealed the proportions of different *vacA* subgenotypes in each ethnic population. More specifically, the *vacA* s1cm1 genotype was not detected in the isolates from the Indian patients, whereas the *vacA* s1cm2 genotype was only detected in the isolates from the Chinese patients.

A previous report demonstrated a higher prevalence of resistance to metronidazole than to other antibiotics in *H. pylori* isolates from Malaysia<sup>[14]</sup>. In the current study, we attempted to further relate the metronidazole susceptibility of *H. pylori* to patient ethnicity and to correlate this susceptibility with the *cagPAI* and *vacA* genotypes. We noted a significant association between the metronidazole-sensitive *H. pylori* strains and Chinese ethnicity, whereas the Malay and Indian patients were more likely to be infected with the metronidazole-resistant strains. This finding may reflect differences in metronidazole use between different ethnic populations. The pattern of metronidazole susceptibility in different ethnicities paralleled the specific genotypes of the infecting strains. For example, the strains of the specific *cagPAI* genotype and *vacA* allele isolated from the Chinese patients were more sensitive to metronidazole.

The presence of frameshift and nonsense mutations in the antibiotic-resistant *H. pylori* strains suggested that these mutations confer resistance to metronidazole. However, more than half of the resistant strains exhibited missense mutations that were also detected in the antibiotic-sensitive strains. This finding implied that *rdxA* is not the only gene involved in the metronidazole-resistant phenotype and thus is not a reliable epidemiological marker. Rather, other genes or mechanisms may be implicated in the generation of resistance<sup>[38-40]</sup>.

We observed no association between the specific *H. pylori* genotypes and the strains' antibiotic susceptibilities

in severe disease. These results may be complicated by the fact that most of the patients in our study population had gastritis. Although the *cagPAI* and *vacA* alleles are important virulence factors in infection, the development of disease is likely to involve a highly complex interplay of many bacterial and/or host factors.

The distribution of the *vacA* s1m2 genotype was broad, as this genotype was detected in the majority of the strains with intact *cagPAI* regions or *cagPAI* rearrangement of type C (positive for more *cagPAI* genes than other types) and the metronidazole-resistant strains. This finding may indicate that the *vacA* s1m2 strains have variable pathogenic properties when combined with other genotypic characteristics. The isolates with the deleted *cagPAI* regions were also primarily linked to metronidazole resistance. As these isolates may induce less inflammation in the host gastric epithelia, their genotypic characteristics may reduce antibiotic delivery and thus hinder the eradication of *H. pylori*. In contrast, the *vacA* s1m2 genotype could not contribute to metronidazole resistance, as this genotype was distributed evenly between the antibiotic-sensitive and -resistant strains<sup>[41,42]</sup>.

In conclusion, we report a large proportion of *H. pylori* isolates harbouring *cagPAI* rearrangement and demonstrate that metronidazole susceptibility varies with patient ethnicity. The distinct distribution of the *H. pylori* *cagPAI* genotypes, *vacA* alleles and metronidazole susceptibilities in the different ethnicities of Malaysia may contribute to varying risk of gastroduodenal diseases. These distinct, patient ethnicity-associated *H. pylori* genotypes may have important clinical and epidemiological implications. Finally, the present study of *H. pylori*-specific genotypes from different host genetic backgrounds enhances our understanding of bacterium-host interactions and bacterial ecology in various niches. Further information on the characteristics of *H. pylori* will allow a more precise identification of virulent strains and a better definition of risk factors in susceptible hosts.

## ACKNOWLEDGMENTS

We thank Universiti Kebangsaan Malaysia for providing both the permission and the facilities to conduct and publish this research. We are also grateful to all of the staff of the Endoscopy and Histopathology Units at UKMMC for their technical help.

## COMMENTS

### Background

The prevalence of *Helicobacter pylori* (*H. pylori*) infection in Malaysia consistently revealed ethnic differences, with Indians exhibiting higher infection rates than the Chinese and Malays. In contrast, peptic-ulcer disease and gastric carcinoma are known to be more prevalent in the Chinese and lowest in the Indians. The great genetic diversity of *H. pylori* may play an important role in the consequences of infection in different hosts. The *cagPAI* and *vacA* genes are well-established *H. pylori* virulence factors that interact with the host cells and disrupt downstream signalling pathways. The *cagPAI* structures, *vacA* alleles

and metronidazole susceptibilities of different strains in hosts of varying genetic makeup may enhance the knowledge of bacterium-host interactions in *H. pylori* infections in multiethnic populations.

### Research frontiers

The specific genotypes stemming from the *cagPAI* and *vacA* alleles were identified in *H. pylori* strains isolated from different ethnic groups. The strains isolated from the Chinese and peptic-ulcer disease (PUD) patients were more sensitive to antibiotics, indicating a selective advantage that occurred during early infection and persisted in chronic infection. In the present study, however, no association between the specific *H. pylori* genotypes and PUD could be determined due to the small number of PUD cases. Consistent with this observation, previous epidemiological studies have reported that less than 20% of patients infected with *H. pylori* are diagnosed as PUD.

### Innovations and breakthroughs

Past reports have highlighted the importance of *H. pylori* genetic diversity in chronic infection. The current study emphasises and adds to findings from the same institution, demonstrating that the genetic background of the *H. pylori* strains may play an important role in the risk of gastroduodenal disease in different ethnic groups.

### Applications

The results of this study provide insight into the effects of the genomic diversity of *H. pylori* on hosts of different genetic backgrounds. Therefore, these findings can be used in the development of advanced screening tools for diagnosing and determining the prognosis of *H. pylori* infection.

### Terminology

The term *cagPAI* is defined as the *cag* pathogenicity island, a common gene sequence believed to be responsible for pathogenesis. This sequence contains approximately 40 kbp of nucleotides encoding over 40 genes. The pathogenicity island is typically absent from the *H. pylori* strains isolated from human carriers of *H. pylori* who remain asymptomatic.

### Peer review

The authors investigated the diversity of the *H. pylori* virulence factors (the *cagPAI* and *vacA* alleles) and metronidazole susceptibilities of strains isolated from patients of different ethnicities. The association between specific *H. pylori* genotypes and patient ethnicity provides insight into the pathogenesis of *H. pylori* infection in different hosts and possibly the different risk factors in *H. pylori* infection.

## REFERENCES

- 1 **Cooke CL**, Huff JL, Solnick JV. The role of genome diversity and immune evasion in persistent infection with *Helicobacter pylori*. *FEMS Immunol Med Microbiol* 2005; **45**: 11-23 [PMID: 15949928 DOI: 10.1016/j.femsim.2005.04.002]
- 2 **Leanza AG**, Matteo MJ, Crespo O, Antelo P, Olmos J, Catalano M. Genetic characterisation of *Helicobacter pylori* isolates from an Argentinean adult population based on *cag* pathogenicity island right-end motifs, *lspA-glmM* polymorphism and *iceA* and *vacA* genotypes. *Clin Microbiol Infect* 2004; **10**: 811-819 [PMID: 15355412]
- 3 **Salama NR**, Gonzalez-Valencia G, Deatherage B, Aviles-Jimenez F, Atherton JC, Graham DY, Torres J. Genetic analysis of *Helicobacter pylori* strain populations colonizing the stomach at different times postinfection. *J Bacteriol* 2007; **189**: 3834-3845 [PMID: 17337568 DOI: 10.1128/JB.01696-06]
- 4 **Hatakeyama M**. *Helicobacter pylori* and gastric carcinogenesis. *J Gastroenterol* 2009; **44**: 239-248 [PMID: 19271114]
- 5 **Kumar S**, Kumar A, Dixit VK. Evidences showing association of interleukin-1B polymorphisms with increased risk of gastric cancer in an Indian population. *Biochem Biophys Res Commun* 2009; **387**: 456-460 [PMID: 19607807]
- 6 **Segal ED**, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by *Helicobacter pylori*. *Proc Natl Acad Sci USA* 1999; **96**: 14559-14564 [PMID: 10588744]
- 7 **Nagiyev T**, Yula E, Abayli B, Koksals F. Prevalence and gen-

- otypes of *Helicobacter pylori* in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova Region of Turkey. *J Clin Microbiol* 2009; **47**: 4150-4153 [PMID: 19846654 DOI: 10.1128/JCM.00605-09]
- 8 **Basso D**, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, Atherton JC. Clinical relevance of *Helicobacter pylori* cagA and vacA gene polymorphisms. *Gastroenterology* 2008; **135**: 91-99 [PMID: 18474244 DOI: 10.1053/j.gastro.2008.03.041]
  - 9 **Nogueira C**, Figueiredo C, Carneiro F, Gomes AT, Barreira R, Figueira P, Salgado C, Belo L, Peixoto A, Bravo JC, Bravo LE, Realpe JL, Plaisier AP, Quint WG, Ruiz B, Correa P, van Doorn LJ. *Helicobacter pylori* genotypes may determine gastric histopathology. *Am J Pathol* 2001; **158**: 647-654 [PMID: 11159201 DOI: 10.1016/S002-9440(10)64006-0]
  - 10 **Alfizah H**, Ramelah M, Rizal AM, Anwar AS, Isa MR. Association of Malaysian *Helicobacter pylori* virulence polymorphisms with severity of gastritis and patients' ethnicity. *Helicobacter* 2012; **17**: 340-349 [PMID: 22967117 DOI: 10.1111/j.1523-5378.2012.00956.x]
  - 11 **Suzuki H**, Nishizawa T, Hibi T. *Helicobacter pylori* eradication therapy. *Future Microbiol* 2010; **5**: 639-648 [PMID: 20353303 DOI: 10.2217/fmb.10.25]
  - 12 **Malfertheiner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
  - 13 **Boyanova L**, Mitov I. Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. *Expert Rev Anti Infect Ther* 2010; **8**: 59-70 [PMID: 20014902]
  - 14 **Ahmad N**, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of *Helicobacter pylori* isolates from Malaysia. *Helicobacter* 2011; **16**: 47-51 [PMID: 21241412 DOI: 10.1111/j.1523-5378.2010.00816.x]
  - 15 **Alfizah H**, Rizal AM, Isa MR, Aminuddin A, Jasmi AY, Ramelah M. Four year analysis of *Helicobacter pylori* infection among patients with dyspepsia in Universiti Kebangsaan Malaysia Medical Centre. *Med Health* 2010; **5**: 13-21
  - 16 **Goh KL**. Epidemiology of *Helicobacter pylori* infection in Malaysia--observations in a multiracial Asian population. *Med J Malaysia* 2009; **64**: 187-192 [PMID: 20527265]
  - 17 **Kaur G**, Naing NN. Prevalence and ethnic distribution of *Helicobacter pylori* infection among endoscoped patients in North Eastern Peninsular Malaysia. *Mal J Med Sci* 2003; **10**: 66-70
  - 18 **Kim JJ**, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, clarithromycin and tetracycline resistance of *Helicobacter pylori* isolates from Korea. *J Antimicrob Chemother* 2001; **47**: 459-461 [PMID: 11266421 DOI: 10.1093/jac/47.4.459]
  - 19 **Solcà NM**, Bernasconi MV, Piffaretti JC. Mechanism of metronidazole resistance in *Helicobacter pylori*: comparison of the rdxA gene sequences in 30 strains. *Antimicrob Agents Chemother* 2000; **44**: 2207-2210 [PMID: 10898705 DOI: 10.1128/AAC.44.8.2207-2210.2000]
  - 20 **Maeda S**, Yoshida H, Ikenoue T, Ogura K, Kanai F, Kato N, Shiratori Y, Omata M. Structure of cag pathogenicity island in Japanese *Helicobacter pylori* isolates. *Gut* 1999; **44**: 336-341 [PMID: 10026317 DOI: 10.1136/gut.44.3.336]
  - 21 **Atherton JC**, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem* 1995; **270**: 17771-17777 [PMID: 7629077 DOI: 10.1074/jbc.270.30.17771]
  - 22 **Patra R**, Chattopadhyay S, De R, Datta S, Chowdhury A, Ramamurthy T, Nair GB, Berg DE, Mukhopadhyay AK. Intact cag pathogenicity island of *Helicobacter pylori* without disease association in Kolkata, India. *Int J Med Microbiol* 2011; **301**: 293-302 [PMID: 21195664 DOI: 10.1016/j.ijmm.2010.10.003]
  - 23 **Suerbaum S**, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002; **347**: 1175-1186 [PMID: 12374879 DOI: 10.1056/NEJMra020542]
  - 24 **Höcker M**, Hohenberger P. *Helicobacter pylori* virulence factors--one part of a big picture. *Lancet* 2003; **362**: 1231-1233 [PMID: 14568748 DOI: 10.1016/S0140-6736(03)14547-3]
  - 25 **Kausar F**, Khan AA, Hussain MA, Carroll IM, Ahmad N, Tiwari S, Shouche Y, Das B, Alam M, Ali SM, Habibullah CM, Sierra R, Megraud F, Sechi LA, Ahmed N. The cag pathogenicity island of *Helicobacter pylori* is disrupted in the majority of patient isolates from different human populations. *J Clin Microbiol* 2004; **42**: 5302-5308 [PMID: 15528729 DOI: 10.1128/JCM.42.11.5302-5308.2004]
  - 26 **Kumar S**, Kumar A, Dixit VK. Diversity in the cag pathogenicity island of *Helicobacter pylori* isolates in populations from North and South India. *J Med Microbiol* 2010; **59**: 32-40 [PMID: 19815664]
  - 27 **Audibert C**, Burucoa C, Janvier B, Fauchère JL. Implication of the structure of the *Helicobacter pylori* cag pathogenicity island in induction of interleukin-8 secretion. *Infect Immun* 2001; **69**: 1625-1629 [PMID: 11179336 DOI: 10.1128/IAI.69.3.1625-1629.2001]
  - 28 **Nilsson C**, Sillén A, Eriksson L, Strand ML, Enroth H, Normark S, Falk P, Engstrand L. Correlation between cag pathogenicity island composition and *Helicobacter pylori*-associated gastroduodenal disease. *Infect Immun* 2003; **71**: 6573-6581 [PMID: 14573679]
  - 29 **Hsu PI**, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y. Clinical presentation in relation to diversity within the *Helicobacter pylori* cag pathogenicity island. *Am J Gastroenterol* 2002; **97**: 2231-2238 [PMID: 12358238 DOI: 10.1111/j.1572-0241.2002.05977.x]
  - 30 **Ikenoue T**, Maeda S, Ogura K, Akanuma M, Mitsuno Y, Imai Y, Yoshida H, Shiratori Y, Omata M. Determination of *Helicobacter pylori* virulence by simple gene analysis of the cag pathogenicity island. *Clin Diagn Lab Immunol* 2001; **8**: 181-186 [PMID: 11139216 DOI: 10.1128/CDLI.8.1.181-186.2001]
  - 31 **Ramelah M**, Aminuddin A, Alfizah H, Isa MR, Jasmi AY, Tan HJ, Rahman AJ, Rizal AM, Mazlam MZ. cagA gene variants in Malaysian *Helicobacter pylori* strains isolated from patients of different ethnic groups. *FEMS Immunol Med Microbiol* 2005; **44**: 239-242 [PMID: 15866222 DOI: 10.1016/j.femsim.2005.02.001]
  - 32 **Ali M**, Khan AA, Tiwari SK, Ahmed N, Rao LV, Habibullah CM. Association between cag-pathogenicity island in *Helicobacter pylori* isolates from peptic ulcer, gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. *World J Gastroenterol* 2005; **11**: 6815-6822 [PMID: 16425389]
  - 33 **Mukhopadhyay AK**, Kersulyte D, Jeong JY, Datta S, Ito Y, Chowdhury A, Chowdhury S, Santra A, Bhattacharya SK, Azuma T, Nair GB, Berg DE. Distinctiveness of genotypes of *Helicobacter pylori* in Calcutta, India. *J Bacteriol* 2000; **182**: 3219-3227 [PMID: 10809703 DOI: 10.1128/JB.182.11.3219-3227.2000]
  - 34 **Lim CC**, Halimah Y. Cancer incidence in Malaysia, 2nd Report. National Cancer Registry Report. Malaysia: Ministry of Health Malaysia, 2003: 78-79
  - 35 **Jang S**, Jones KR, Olsen CH, Joo YM, Yoo YJ, Chung IS, Cha JH, Merrell DS. Epidemiological link between gastric disease and polymorphisms in VacA and CagA. *J Clin Microbiol* 2010; **48**: 559-567 [PMID: 19955279 DOI: 10.1128/JCM.01501-09]
  - 36 **Wang J**, van Doorn LJ, Robinson PA, Ji X, Wang D, Wang

- Y, Ge L, Telford JL, Crabtree JE. Regional variation among *vacA* alleles of *Helicobacter pylori* in China. *J Clin Microbiol* 2003; **41**: 1942-1945 [PMID: 12734231 DOI: 10.1128/JCM.41.5.1942-1945.2003]
- 37 **Miernyk K**, Morris J, Bruden D, McMahon B, Hurlburt D, Sacco F, Parkinson A, Hennessy T, Bruce M. Characterization of *Helicobacter pylori* *cagA* and *vacA* genotypes among Alaskans and their correlation with clinical disease. *J Clin Microbiol* 2011; **49**: 3114-3121 [PMID: 21752979 DOI: 10.1128/JCM.00469-11]
- 38 **Francesco VD**, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of *Helicobacter pylori* antibiotic resistance: An updated appraisal. *World J Gastrointest Pathophysiol* 2011; **2**: 35-41 [PMID: 21860834 DOI: 10.4291/wjgp.v2.i3.35]
- 39 **Jiang K**, Zhang JZ, Pan GZ. Mechanism of metronidazole resistance of *Helicobacter pylori*. *Zhongguo Xiaohua Jibing Zazhi* 2001; **2**: 95-99
- 40 **Hoffman PS**, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJ. Metabolic activities of metronidazole-sensitive and -resistant strains of *Helicobacter pylori*: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. *J Bacteriol* 1996; **178**: 4822-4829 [PMID: 8759844]
- 41 **Elviss NC**, Owen RJ, Breathnach A, Palmer C, Shetty N. *Helicobacter pylori* antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000. *J Med Microbiol* 2005; **54**: 567-574 [PMID: 15888466]
- 42 **Godoy AP**, Ribeiro ML, Benvenuto YH, Vitiello L, Miranda Mde C, Mendonça S, Pedrazzoli J. Analysis of antimicrobial susceptibility and virulence factors in *Helicobacter pylori* clinical isolates. *BMC Gastroenterol* 2003; **3**: 20 [PMID: 12911839 DOI: 10.1186/1471-230X-3-20]

P-Reviewer Mori N S-Editor Gou SX L-Editor A  
E-Editor Zhang DN

